Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 2, 2008, Pages 258-264

  Wang, L ^a   Giannoudis, A ^a   Lane, S ^b   Williamson, P ^b   Pirmohamed, M ^b   Clark, R E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; OCTAMER TRANSCRIPTION FACTOR-1; P-GLYCOPROTEIN; PATIENT SELECTION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME;

EID: 38349193809     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100268     Document Type: Article

References (46)

1. Hahn, E.A. et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J. Clin. Oncol. 21, 2138-2146 (2003).
2. O'Brien, S.G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
3. Druker, B.J., et al. & IRIS Investigators Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
4. Kantarjian, H.M. et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin. Cancer Res. 8, 2177-2187 (2002).
5. Kantarjian, H.M. et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin. Cancer Res. 8, 2167-2176 (2002).
6. Campbell, L.J., Patsouris, C., Rayeroux, K.C., Somana, K., Januszewicz, E.H. & Szer, J. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet. Cytogenet. 139, 30-33 (2002).
7. Morel, F. et al. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur. J. Haematol. 70, 235-239 (2003).
8. Burchert, A. et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19, 1774-1782 (2005).
9. Nardi, V., Azam, M. & Daley, G.Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11, 35-43 (2004).
10. Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472-3475 (2002).
11. Branford, S. et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-283 (2003).
12. Soverini, S. et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J. Clin. Oncol. 23, 4100-4109 (2005).
13. Kreil, S. et al. Management and clinical outcome of CML patients after imatinib resistance associated with ABL kinase domain mutations. Blood 102(Suppl 1): 71a (2003) [abstract].
14. Willis, S. et al. High sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106, 2128-2137 (2005).
15. Hegedus, T., Orfi, L., Seprodi, A., Varadi, A., Sarkadi, B. & Keri, G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587, 318-325 (2002).
16. Hoffmann, U. & Kroemer, H.K. The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab. Rev. 36, 669-701 (2004).
17. Mahon, F.X. et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373 (2003).
18. Illmer, T. et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18, 401-408 (2004).
19. Widmer, N., Colombo, S., Buclin, T. & Decosterd, L.A. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 102, 1142 (2003).
20. Ozvegy-Laczka, C. et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65, 1485-1495 (2004).
21. Burger, H. et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104, 2940-2942 (2004).
22. Houghton, P.J. et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 64, 2333-2337 (2004).
23. Jordanides, N.E., Jorgensen, H.G., Holyoake, T.L. & Mountford, J.C. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108, 1370-1373 (2006).
24. Nakanishi, T., Shiozawa, K., Hassel, B.A. & Ross, D.D. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108, 678-684 (2006).
25. Burger, H. et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol. Ther. 4, 747-752 (2005).
26. Lange, T. et al. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 101, 2152-2155 (2003).
27. Burger, H. & Nooter, K. Pharmacokinetic resistance to imatinib mesylate. Cell Cycle 3, e206-e209 (2004).
28. Thomas, J., Wang, L., Clark, R.E. & Pirmohamed, M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104, 3739-3745 (2004).
29. Gründemann, D., Gorboulev, V., Gambaryan, S., Veyhl, M. & Koepsell, H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372, 549-552 (1994).
30. Jonker, J.W. & Schinkel, A.H. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2 and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. 308, 2-9 (2004).
31. Wang, D.S., Kusuhara, H., Kato, Y., Jonker, J.W., Schinkel, A.H. & Sugiyama, Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol. Pharmacol. 63, 844-848 (2003).
32. Tipping, A.J., Deininger, M.W., Goldman, J.M. & Melo, J.V. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp. Hematol. 31, 1073-1080 (2003).
33. Crossman, L.C. et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 90, 459-464 (2005).
34. Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002).
35. Roy, L. et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108, 1478-1484 (2006).
36. Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002).
37. White, D.L. et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108, 697-704 (2006).
38. Crossman, L.C., Druker, B.J. & Deininger, M.W. hOCT1 and resistance to imatinib. Blood 106, 1133-1134 (2005).
39. Ciarimboli, G. et al. Regulation of the human organic cation transporter hOCT1. J. Cell Physiol. 201, 420-428 (2004).
40. Itoda, M. et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab. Pharmacokinet. 19, 308-312 (2004).
41. Sakata, T. et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem. Biophys. Res. Commun. 313, 789-793 (2004).
42. Denk, G.U., Soroka, C.J., Mennone, A., Koepsell, H., Beuers, U. & Boyer, J.L. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology 39, 1382-1389 (2004).
43. Wang, L., Pearson, K., Pillitteri, L., Ferguson, J.E. & Clark, R.E. Serial monitoring of BCR-ABL by peripheral blood real time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br. J. Haematol. 118, 771-777 (2002).
44. Wang, L., Knight, K., Lucas, C. & Clark, R.E. Serial BCR-ABL transcript monitoring may predict emergence of BCR-ABL kinase mutations in imatinib treated chronic myeloid leukaemia. Haematologica 91, 235-239 (2006).
45. Biermann, J. et al. Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am. J. Physiol. Cell Physiol. 290, C1521-C1531 (2006).
46. Kalbfleisch, J.D. & Prentice, R.L. The Statistical Analysis of Failure Time Data (John Wiley and Sons, Hoboken, NJ, 1980).